ArticleThe New England journal of medicine2019
A Longitudinal Study of Ebola Sequelae in Liberia.
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 110 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Partnership for Research on Ebola Virus (PREVAIL) Prevail III: Ebola Natural History Study
Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases
Community Preparedness for Outbreak Response and Readiness for ZEBOV Vaccination in Liberia
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Who cites it
110 citing papers in PubMed, 4 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.The American journal of tropical medicine and hygiene · 2025Pooled it
- Prevalence of somatic symptoms among Ebola Virus Disease (EVD) survivors in Africa: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Psychiatric symptoms in Long-COVID patients: a systematic review.Frontiers in psychiatry · 2023Pooled it
- Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.The Lancet. Microbe · 2024Trial
- PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- The impact of the 2014 Ebola epidemic on HIV disease burden and outcomes in Liberia West Africa.PloS one · 2021Trial
- Ebola virus and Sudan virus infection in humans: a comparison to inform vaccine research and development.Emerging microbes & infections · 2026Review
- Metabolic basis of post-infectious sequelae after Ebola virus disease.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Marburg virus persistence and clinical complications among recovered persons in Rwanda: a longitudinal study protocol.BMJ open · 2026Article
- Article
- Neurological Manifestations in Adult Survivors of Ebola Virus Disease.JAMA neurology · 2026Article
- Host-virus determinants of Ebola virus persistence in a human cerebral organoid model.Nature microbiology · 2026Article
- Identification of Contacts With High Rates of Missed and Asymptomatic Infection Following an Outbreak of Ebola Virus Disease: A Seroepidemiological Study in Likati Health Zone, Democratic Republic of the Congo.Open forum infectious diseases · 2026Article
- Pediatric Ebola Eye Disease in the PREVAIL (Partnership for Research on Ebola Virus in Liberia) III Longitudinal Cohort Study.Ophthalmology science · 2026Article
- Identification of a unique humoral immune signature of Sudan ebolavirus persistence in human survivors.Research square · 2026Article
- Considerations for epidemiological studies investigating emerging post-acute infection syndromes: Long Covid as a case study.EClinicalMedicine · 2026Review
- Comparison of Four Assays That Measure Antibodies to Ebola Virus Glycoprotein.bioRxiv : the preprint server for biology · 2026Article
- Serologic Evidence of Hemorrhagic Fever Virus Spillover in Rural Liberia.Open forum infectious diseases · 2026Article
- Platelet-like particles released from Ebola virus-infected megakaryocytic cells behave like virus-like particles.PLoS pathogens · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMultiple health problems have been reported in survivors of Ebola virus disease (EVD). Attribution of these problems to the disease without a control group for analysis is difficult.
methodsWe enrolled a cohort of EVD survivors and their close contacts and prospectively collected data on symptoms, physical examination findings, and laboratory results. A subset of participants underwent ophthalmologic examinations. Persistence of Ebola virus (EBOV) RNA in semen samples from survivors was determined.
resultsA total of 966 EBOV antibody-positive survivors and 2350 antibody-negative close contacts (controls) were enrolled, and 90% of these participants were followed for 12 months. At enrollment (median time to baseline visit, 358 days after symptom onset), six symptoms were reported significantly more often among survivors than among controls: urinary frequency (14.7% vs. 3.4%), headache (47.6% vs. 35.6%), fatigue (18.4% vs. 6.3%), muscle pain (23.1% vs. 10.1%), memory loss (29.2% vs. 4.8%), and joint pain (47.5% vs. 17.5%). On examination, more survivors than controls had abnormal abdominal, chest, neurologic, and musculoskeletal findings and uveitis. Other than uveitis (prevalence at enrollment, 26.4% vs. 12.1%; at year 1, 33.3% vs. 15.4%), the prevalence of these conditions declined during follow-up in both groups. The incidence of most symptoms, neurologic findings, and uveitis was greater among survivors than among controls. EBOV RNA was detected in semen samples from 30% of the survivors tested, with a maximum time from illness to detection of 40 months.
conclusionsA relatively high burden of symptoms was seen in all participants, but certain symptoms and examination findings were more common among survivors. With the exception of uveitis, these conditions declined in prevalence during follow-up in both groups. Viral RNA in semen persisted for a maximum of 40 months. (Funded by the National Institute of Allergy and Infectious Diseases and the National Eye Institute; PREVAIL III ClinicalTrials.gov number, NCT02431923.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.